p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation

Nature Cell Biology

Volumn 10, Issue 5, 2008, Pages 611-618

  Kawauchi, Keiko ^a   Araki, Keigo ^a   Tobiume, Kei ^a   Tanaka, Nobuyuki ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER 3; I KAPPA B KINASE; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; RAS PROTEIN; SYNAPTOTAGMIN I;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; FIBROBLAST CULTURE; GLUCOSE METABOLISM; GLYCOLYSIS; INHIBITION KINETICS; METABOLIC REGULATION; MOUSE; NONHUMAN; ONCOGENE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; FIBROBLASTS; GENES, RAS; GLUCOSE; GLUCOSE TRANSPORTER TYPE 3; GLYCOLYSIS; I-KAPPA B KINASE; LACTIC ACID; MICE; MICE, KNOCKOUT; RAS PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 43049139541     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb1724     Document Type: Article

References (30)

1. Warburg, O. On respiratory impairment in cancer cells. Science 124, 269-270 (1956).
2. Kim, J. W. & Dang, C. V. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 66, 8927-8930 (2006).
3. Dang, C. V. & Semenza, G. L. Oncogenic alterations of metabolism. Trends Biochem. Sci. 24, 68-72 (1999).
4. Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? Nature Rev. Cancer 4, 891-899 (2004).
5. Meller, J., Sahlmann, C. O. & Scheel, A. K. 18F-FDG PET and PET/CT in fever of unknown origin. J. Nucl. Med. 48, 35-45 (2007).
6. Hamroun, D. et al. The UMD TP53 database and website: Update and revisions. Hum. Mutat. 27, 14-20 (2006).
7. Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307-310 (2000).
8. Lowe, S. W., Jacks, T., Housman, D. E. & Ruley, H. E. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc. Natl Acad. Sci. USA 91, 2026-2030 (1994).
9. Tanaka, N. et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 77, 829-839 (1994).
10. Bartek, J., Lukas, J. & Bartkova, J. DNA damage response as an anti-cancer barrier: Damage threshold and the concept of 'conditional haploinsufficiency'. Cell Cycle 6, 2344-2347 (2007).
11. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602 (1997).
12. Finco, T. S. et al. Oncogenic Ha-Ras-induced signaling activates NF-κB transcriptional activity, which is required for cellular transformation. J. Biol. Chem. 272, 24113-24116 (1997).
13. Rayet, B. & Gelinas, C. Aberrant rel/nfκb genes and activity in human cancer. Oncogene 18, 6938-6947 (1999).
14. Ryan, K. M., Ernst, M. K., Rice, N. R. & Vousden, K. H. Role of NF-κB in p53-mediated programmed cell death. Nature 404, 892-897 (2000).
15. Webster, G. A. & Perkins, N. D. Transcriptional cross talk between NF-κB and p53. Mol. Cell. Biol. 19, 3485-3495 (1999).
16. Huang, W. C., Ju, T. K., Hung, M. C. & Chen, C. C. Phosphorylation of CBP by IKKα promotes cell growth by switching the binding preference of CBP from p53 to NF-κB. Mol. Cell 26, 75-87 (2007).
17. Janssens, S. & Tschopp, J. Signals from within: The DNA-damage-induced NF-κB response. Cell Death Differ. 13, 773-784 (2006).
18. Kondoh, H. et al. Glycolytic enzymes can modulate cellular life span. Cancer Res. 65, 177-185 (2005).
19. Schwartzenberg-Bar-Yoseph, F., Armoni, M. & Karnieli, E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 64, 2627-2633 (2004).
20. Matoba, S. et al. p53 regulates mitochondrial respiration. Science 312, 1650-1653 (2006).
21. Mayo, M. W. & Baldwin, A. S. The transcription factor NF-κB: Control of oncogenesis and cancer therapy resistance. Biochim. Biophys. Acta 1470, M55-62 (2000).
22. Zhong, H., Voll, R. E. & Ghosh, S. Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the co-activator CBP/p300. Mol. Cell 1, 661-671 (1998).
23. Macheda, M. L., Rogers, S. & Best, J. D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell Physiol. 202, 654-662 (2005).
24. Medina, R. A. & Owen, G. I. Glucose transporters: Expression, regulation and cancer. Biol. Res. 35, 9-26 (2002).
25. Pahl, H. L. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18, 6853-6866 (1999).
26. Anest, V. et al. A nucleosomal function for IκB kinase-α in NF-κB-dependent gene expression. Nature 423, 659-663 (2003).
27. Yamamoto, Y., Verma, U. N., Prajapati, S., Kwak, Y. T. & Gaynor, R. B. Histone H3 phosphorylation by IKK-α is critical for cytokine-induced gene expression. Nature 423, 655-659 (2003).
28. Weisz, L. et al. Mutant p53 enhances nuclear factor κB activation by tumor necrosis factor α in cancer cells. Cancer Res. 67, 2396-2401 (2007).
29. Bensaad, K. et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-120 (2006).
30. Sato, M. et al. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-α/β gene induction. Immunity 13, 539-548 (2000).